Risk Assessment of Drug‐Induced Long QT Syndrome for Some COVID‐19 Repurposed Drugs
Open Access
- 5 September 2020
- journal article
- research article
- Published by Wiley in Clinical and Translational Science
- Vol. 14 (1), 20-28
- https://doi.org/10.1111/cts.12882
Abstract
The risk‐benefit ratio associated with the use of repurposed drugs to treat 2019 SARS‐CoV‐2 related infectious disease (COVID‐19) is complicated since benefits are awaited, not proven. A thorough literature search was conducted to source information on the pharmacological properties of 5 drugs and 1 combination (azithromycin, chloroquine, favipiravir, hydroxychloroquine, remdesivir, and lopinavir/ritonavir) repurposed to treat COVID‐19. A risk assessment of drug‐induced Long QT Syndrome (LQTS) associated with COVID‐19 repurposed drugs was performed and compared to 23 well‐known torsadogenic and 10 low torsadogenic risk compounds. Computer calculations were performed using pharmacokinetic and pharmacodynamic data, including affinity to block the rapid component of the delayed rectifier cardiac potassium current (IKr) encoded by the human ether‐a‐go‐go gene (hERG), propensity to prolong cardiac repolarization (QT interval) and cause torsade de pointes (TdP). Seven different LQTS indices were calculated and compared. The U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database was queried with specific key words relating to arrhythmogenic events. Estimators of LQTS risk levels indicated a very high or moderate risk for all COVID‐19 repurposed drugs with the exception for azithromycin, although cases of TdP have been reported with this drug. There was excellent agreement among the various indices used to assess risk of drug‐induced LQTS for the 6 repurposed medications and 23 torsadogenic compounds. Based on our results, monitoring of the QT interval shall be performed when some COVID‐19 repurposed drugs are used, as such monitoring is possible for hospitalized patients or with the use of biodevices for outpatients.Keywords
This publication has 40 references indexed in Scilit:
- Lengthening of Cardiac Repolarization in Isolated Guinea Pigs Hearts by Sequential or Concomitant Administration of Two IKr BlockersJournal of Pharmaceutical Sciences, 2011
- Simulation of the Undiseased Human Cardiac Ventricular Action Potential: Model Formulation and Experimental ValidationPLoS Computational Biology, 2011
- How to improve R&D productivity: the pharmaceutical industry's grand challengeNature Reviews Drug Discovery, 2010
- T-705 (favipiravir) activity against lethal H5N1 influenza A virusesProceedings of the National Academy of Sciences of the United States of America, 2009
- Azithromycin‐Induced Torsade De PointesPacing and Clinical Electrophysiology, 2007
- Blockade of HERG channels by HIV protease inhibitorsThe Lancet, 2005
- Drug Interactions Between Antiretroviral Drugs and Comedicated AgentsClinical Pharmacokinetics, 2003
- Interactions among Drugs for HIV and Opportunistic InfectionsThe New England Journal of Medicine, 2001
- Concomitant Block of the Rapid (IKr) and Slow (IKs) Components of the Delayed Rectifier Potassium Current is Associated With Additional Drug Effects on Lengthening of Cardiac RepolarizationJournal of Cardiovascular Pharmacology and Therapeutics, 1999
- Clinical Pharmacokinetics and Metabolism of ChloroquineClinical Pharmacokinetics, 1996